Risk factors of treatment failure in community acquired pneumonia:: implications for disease outcome

被引:220
|
作者
Menéndez, R
Torres, A
Zalacaín, R
Aspa, J
Villasclaras, JJM
Borderías, L
Moya, JMB
Ruiz-Manzano, J
de Castro, FR
Blanquer, J
Pérez, D
Puzo, C
Gascón, FS
Gallardo, J
Alvarez, C
Molinos, L
机构
[1] Hosp Univ La Fe, Serv Neumol, Valencia 46009, Spain
[2] Hosp Clin Barcelona, Inst Neumol & Alergia, Barcelona, Spain
[3] Hosp Cruces, Serv Neumol, Bilbao, Spain
[4] Hosp Princesa, Serv Neumol, Madrid, Spain
[5] Hosp Carlos Haya, Serv Neumol, Malaga, Spain
[6] Hosp San Jorge, Serv Neumol, Huesca, Spain
[7] Hosp Virgen Macarena, Serv Neumol, Seville, Spain
[8] Hosp Badalona Germans Trias & Pujol, Serv Neumol, Badalona, Spain
[9] Hosp Dr Negrin, Serv Neumol, Las Palmas Gran Canaria, Spain
[10] Hosp Clin, Serv Neumol, Cuidados Intens, Valencia, Spain
[11] Hosp San Pablo, Serv Neumol, Barcelona, Spain
[12] Hosp Gen Univ, Serv Neumol, Murcia, Spain
[13] Gen Hosp, Serv Neumol, Guadalajara, Spain
[14] Hosp 12 Octubre, Serv Neumol, E-28041 Madrid, Spain
[15] Hosp Ntra Sra Covadonga, Serv Neumol, Oviedo, Spain
关键词
D O I
10.1136/thx.2003.017756
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: An inadequate response to initial empirical treatment of community acquired pneumonia (CAP) represents a challenge for clinicians and requires early identification and intervention. A study was undertaken to quantify the incidence of failure of empirical treatment in CAP, to identify risk factors for treatment failure, and to determine the implications of treatment failure on the outcome. Methods: A prospective multicentre cohort study was performed in 1424 hospitalised patients from 15 hospitals. Early treatment failure (<72 hours), late treatment failure, and in-hospital mortality were recorded. Results: Treatment failure occurred in 215 patients (15.1%): 134 early failure (62.3%) and 81 late failure (37.7%). The causes were infectious in 86 patients (40%), non-infectious in 34 (15.8%), and undetermined in 95. The independent risk factors associated with treatment failure in a stepwise logistic regression analysis were liver disease, pneumonia risk class, leucopenia, multilobar CAP, pleural effusion, and radiological signs of cavitation. Independent factors associated with a lower risk of treatment failure were influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease (COPD). Mortality was significantly higher in patients with treatment failure (25% v 2%). Failure of empirical treatment increased the mortality of CAP 11-fold after adjustment for risk class. Conclusions: Although these findings need to be confirmed by randomised studies, they suggest possible interventions to decrease mortality due to CAP.
引用
收藏
页码:960 / 965
页数:6
相关论文
共 50 条
  • [1] Risk Factors for Treatment Failure in Hospitalized Patients with Community-Acquired Pneumonia
    Kinoshita, K.
    Kanemura, H.
    Nishimura, N.
    Hayashi, K.
    Gilmour, S.
    Tamura, T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] Patient risk factors in community-acquired pneumonia infections outcome following treatment with gemifloxacin
    Morrissey, I
    File, TM
    Mandell, LA
    Tillotson, GS
    [J]. CHEST, 2005, 128 (04) : 372S - 372S
  • [3] Treatment failure in community-acquired pneumonia
    Menendez, Rosario
    Torres, Antoni
    [J]. CHEST, 2007, 132 (04) : 1348 - 1355
  • [4] Risk factors of severe community acquired pneumonia
    Arancibia, F
    Ruiz, M
    Ewig, S
    Marcos, MA
    Raño, A
    Martinez, JA
    Mensa, J
    Torres, A
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A921 - A921
  • [5] Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia
    Genné, D
    Sommer, R
    Kaiser, L
    Saaïdia, A
    Pasche, A
    Unger, P
    Lew, D
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2006, 25 (03) : 159 - 166
  • [6] Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia
    D. Genné
    R. Sommer
    L. Kaiser
    A. Saaïdia
    A. Pasche
    P. F. Unger
    D. Lew
    [J]. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25 : 159 - 166
  • [7] Community-acquired pneumonia caused by Pseudomonas aeruginosa:: incidence, risk factors, and outcome
    Garcia-Vidal, C.
    Muñoz, L.
    Mykietiuk, A.
    Verdaguer, R.
    Carratalà, J.
    Gudiol, F.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S83 - S83
  • [8] Markers of treatment failure in hospitalised community acquired pneumonia
    Menendez, R.
    Cavalcanti, M.
    Reyes, S.
    Mensa, J.
    Martinez, R.
    Marcos, M. A.
    Filella, X.
    Niederman, M.
    Torres, A.
    [J]. THORAX, 2008, 63 (05) : 447 - 452
  • [9] Implications for macrolide treatment in community-acquired pneumonia
    Mundy, LM
    Oldach, D
    Auwaerter, PG
    Gaydos, CA
    Moore, RD
    Bartlett, JG
    Quinn, TC
    [J]. CHEST, 1998, 113 (05) : 1201 - 1206
  • [10] Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients
    Han, Xiudi
    Liu, Xuedong
    Chen, Liang
    Wang, Yimin
    Li, Hui
    Zhou, Fei
    Xing, Xiqian
    Zhang, Chunxiao
    Suo, Lijun
    Wang, Jinxiang
    Yu, Guohua
    Wang, Guangqiang
    Yao, Xuexin
    Yu, Hongxia
    Wang, Lei
    Liu, Meng
    Xue, Chunxue
    Liu, Bo
    Zhu, Xiaoli
    Li, Yanli
    Xiao, Ying
    Cui, Xiaojing
    Li, Lijuan
    Cao, Bin
    [J]. BMC INFECTIOUS DISEASES, 2020, 20 (01)